A single-center, randomized controlled study for invasive pulmonary aspergillosis in patients with liver failure with different loads of voriconazole therapy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900024124

Enrollment

Unknown

Registered

2019-06-26

Start date

2019-07-01

Completion date

Unknown

Last updated

2019-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Invasive Pulmonary Aspergillosis

Interventions

Experimental group:Voriconazole 6mg/kg, 2mg/kg

Control group:Voriconazole 6mg/kg, 6mg/kg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients with signing of informed consent and confirming to enrollment; (2) Male or female, aged 18-65 years; (3) Patients with acute-on-chronic liver failure meet a criterion of guidelines for diagnosis and treatment of liver failure in 2018; (4) Patients with invasive pulmonary aspergillosis meet a criterion of EORTC/MSG consensus definition of invasive Aspergillus infection in 2008, including proven and probable cases.

Exclusion criteria

Exclusion criteria: (1) Pregnant or lactating women; (2) Patient with acute fatty liver in pregnancy; (3) Patient with HIV co-infection; (4) Patient accompany with severe underlying diseases; (5) History of allergic to voriconazole.

Design outcomes

Primary

Measure	Time frame
Antifungal effect;Voriconazole plasma concentration;	—

Secondary

Measure	Time frame
CT lung imaging;Blood routine, CRP, PCT, ESR, FER, LDH, G test, GM test;hepatic and renal function;coagulation function;mortality;adverse event incidence;	—

Countries

China

Contacts

Public ContactLiu Jing

The Third Affliated Hospital of Sun Yat-Sen University

jingliu_1203@hotmail.com+86 13556051920

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026